Marrow transplantation have taught us that hematopoiesis is supported by multipotent hematopoietic stem cells that can maintain or reconstitute the various blood cell lineages throughout life. Despite advances in our understanding of lineage commitment, this has not translated into improved approaches for treating lineage specific cytopenias. The goal of our application is to further our understanding of lineage commitment and use this knowledge to develop molecular interventions that will drive hematopoiesis toward desired lineages both in vitro and in vivo. The application is specifically focused on megakaryopoiesis, because of the clinical importance of post-transplant thrombocytopenia, and to maximize synergy with our UOl partners at Childrens Hospital of Philadelphia. Towards this goal we propose a multifaceted program with 4 Aims, with each aim involving two or more investigators from the FHCRC/UW Consortium.
In Aim 1, Drs Fero, Paddington and Torok-Storb will generate molecular profiles of functionally defined progenitors in the stem cell to platelet pathway from mouse, dog, and man. These three experimental models have complementary strengths that allow for a comprehensive approach including a robust preclinical in vivo model that can predict clinical outcomes.
In Aim 2 these same investigators will gene modify the defined progenitor cells to express lineage-stage-specific reporters for use in a high content, high through put siRNA screening assays to identify changes in the microenvironment that will control progenitor fate.
A third Aim will test the proliferation and differentation potential of distinct progenitor subsets in response to conditionally activated signaling molecules. For this purpose Drs Blau and Emery will use signaling molecule derivatives that can be activated in response to small molecule drugs called chemical inducers of dimerization (CIDs).
In Aim 4, Drs Kiem and Blau will exploit the canine model of thrombocytopenia to test gene products identified in Aim 2, and cell products expanded in Aim 3 to improve the platelet count in vivo. These in vivo studies in the dog model will establish the safety and efficacy of these therapies in a highly relevant preclinical model

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01HL099993-05S1
Application #
8725272
Study Section
Special Emphasis Panel (ZHL1-CSR-J (S1))
Program Officer
Thomas, John
Project Start
2009-09-30
Project End
2016-04-30
Budget Start
2013-09-01
Budget End
2014-04-30
Support Year
5
Fiscal Year
2013
Total Cost
$1,760
Indirect Cost
$760
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Meng, Ronghua; Wu, Jie; Harper, Dawn C et al. (2015) Defective release of α granule and lysosome contents from platelets in mouse Hermansky-Pudlak syndrome models. Blood 125:1623-32
Wang, Yuhuan; Hayes, Vincent; Jarocha, Danuta et al. (2015) Comparative analysis of human ex vivo-generated platelets vs megakaryocyte-generated platelets in mice: a cautionary tale. Blood 125:3627-36
Belay, Eyayu; Miller, Chris P; Kortum, Amanda N et al. (2015) A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor. Blood 125:1025-33
Antony-Debré, Iléana; Manchev, Vladimir T; Balayn, Nathalie et al. (2015) Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. Blood 125:930-40
Sperber, Henrik; Mathieu, Julie; Wang, Yuliang et al. (2015) The metabolome regulates the epigenetic landscape during naive-to-primed human embryonic stem cell transition. Nat Cell Biol 17:1523-35
Byrska-Bishop, Marta; VanDorn, Daniel; Campbell, Amy E et al. (2015) Pluripotent stem cells reveal erythroid-specific activities of the GATA1 N-terminus. J Clin Invest 125:993-1005
Shaham, Lital; Vendramini, Elena; Ge, Yubin et al. (2015) MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome. Blood 125:1292-301
Ilagan, Janine O; Ramakrishnan, Aravind; Hayes, Brian et al. (2015) U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res 25:14-26
Suter, Steven E; Hamilton, Matthew J; Sullivan, Edmund W et al. (2015) Allogeneic hematopoietic cell transplantation in a dog with acute large granular lymphocytic leukemia. J Am Vet Med Assoc 246:994-7
Kim, Eunhee; Ilagan, Janine O; Liang, Yang et al. (2015) SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell 27:617-30

Showing the most recent 10 out of 38 publications